Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat oncology and autoimmune diseases, announced the appointment of Joseph Bolen, Ph.D., as...
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a research collaboration with ATTMOS as...
AbbVie and Xilio Therapeutics, Inc., a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration...
Boundless Bio a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, announced...
AbbVie and Neomorph, announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.
Molecular glue degraders...
